Changes in donor exosomes could indicate transplant rejection risk | Dihydroartemisinin-piperaquine tested for prevention of placental malaria | Memgen may partner with ImmunoCellular on cancer treatments
March 24, 2017
News for the transfusion medicine and cellular therapy community
University of Pennsylvania investigators evaluated blood plasma samples from transplant recipients and found that modifications in donor exosomes can be an early indication of transplant rejection, according to research in the Journal of Clinical Investigation. The study was supported by the NIH.
Reading Between Blood Samples Masimo noninvasive and continuous total hemoglobin (SpHb®) offers real-time visibility
to changes in hemoglobin between invasive blood sampling. SpHb may provide additional insight when the hemoglobin trend is:
• Stable and the clinician may otherwise think hemoglobin is dropping
• Rising and the clinician may otherwise think hemoglobin is not rising fast enough
• Dropping and the clinician may otherwise think hemoglobin is stable
A randomized study of 200 HIV-positive pregnant women in Uganda found that the addition of monthly dihydroartemisinin-piperaquine to a daily regimen of trimethoprim-sulfamethoxazole did not reduce the risk of placental malaria. The findings were reported in the Journal of Infectious Diseases.
A letter of intent to collaborate has been signed by ImmunoCellular Therapeutics and Memgen. The potential partnership would focus on clinical studies combining Memgen's viral cancer immunotherapy ISF35 with two immunotherapy candidates from ImmunoCellular.
BioLineRx reported that the interim results of an open-label, Phase II trial show that one injection of its BL-8040 drug candidate was as effective at mobilizing stem cells for transplantation as 4-6 doses of granulocyte colony-stimulating factor. The second part of the trial is scheduled to include 24 pairs of donors and recipients.
Abstract Deadline Extended – March 29 Join us this year in San Diego, June 8-10 for the 15th International Cord Blood Symposium. Submit your abstract for consideration to present at this year’s Symposium and qualify to win one of three “Best Abstract” awards. The deadline to submit an abstract is March 29.
Shire's drug candidate SHP655 has been granted fast-track designation by the FDA as a treatment for acute episodes of hereditary thrombotic thrombocytopenic purpura in patients with a deficiency in the enzyme ADAMTS13. The company plans to initiate a late-stage trial assessing SHP655's treatment and prevention capabilities.
Today is World Tuberculosis Day, commemorating the date in 1882 when Dr. Robert Koch announced his discovery of Mycobacterium tuberculosis, the bacillus that causes tuberculosis. This year the theme of World TB Day is "Unite to End TB." Although tuberculosis is preventable and curable, many people in the United States still suffer from this disease.